Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.81 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.81 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.71 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334103 | 1.00 | MAOB (0.81) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL16382869 | 0.98 | MAOB (0.78) | MAOBALOX5TRPV1PELI1KDM4E | |
| SCHEMBL1560606 | 0.98 | MAOB (0.78) | MAOBALOX5TRPV1PELI1KDM4E | |
| SCHEMBL17340469 | 0.90 | ALOX5 (1.00) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL10932270 | 0.90 | ALOX5 (1.00) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL29738484 | 0.90 | ALOX5 (1.00) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL29738485 | 0.88 | ALOX5 (0.97) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL19051846 | 0.87 | TRPV1 (0.70) | MAOBALOX5TRPV1PELI1NPC1 | |
| SCHEMBL2484738 | 0.85 | TRPV1 (0.72) | MAOBALOX5TRPV1NPC1RAB9A | |
| SCHEMBL2484236 | 0.85 | ALOX5 (0.60) | MAOBALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | claimed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | claimed |
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | disclosed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | ABL1, MCL1, SRC | MAOB 2070/4885ALOX5 547/4885TRPV1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.